Mink Therapeutics (INKT) Q1 2025 earnings summary

Executive summary

• Achieved significant clinical milestones, including complete remission in testicular cancer and active enrollment in Phase 2 gastric cancer trials, with new data presented at major oncology conferences.

• Advanced off-the-shelf iNKT cell therapies for solid tumors and immune diseases, with proprietary manufacturing enabling scalable production and a pipeline including next-gen engineered programs.

• Engaged in strategic partnership discussions and collaborations to expand platform reach and secure additional funding.

• Secured probable NIAID funding for the GVHD program, enhancing non-dilutive capital and external validation.

• Management expects continued operating losses and negative cash flows, with substantial doubt about the ability to continue as a going concern pending anticipated but not guaranteed funding.

Financial highlights

• Ended Q1 2025 with a cash balance of $3.2 million, down from $4.6 million at year-end 2024.

• Net loss for Q1 2025 was $2.8 million ($0.70 per share), improved from $3.8 million ($1.10 per share) in Q1 2024.

• Cash used in operations was $1.3 million for Q1 2025, down from $2.5 million in Q1 2024.

• Research and development expenses decreased 51% year-over-year to $1.3 million, while general and administrative expenses remained flat at $1.3 million.

• Weighted average shares outstanding were 3.97 million for Q1 2025.

Outlook and guidance

• On track to present initial efficacy data from the phase II gastric cancer trial in the second half of 2025, with updates possible by year-end or early next year.

• Anticipates formal NIAID funding award by June 2025 to support the GVHD program, with optimism for continued government support.

• Plans to advance one or more partnership proposals in the near term to diversify capital and accelerate development.

• IND submission for MINK-215 is planned for 2025; further advancement of agenT-797 in ARDS is contingent on external collaborations.

• Management expects continued operating losses and will seek additional funding via partnerships, collaborations, and non-dilutive financing.